The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-08. Anything still debated is marked as such rather than presented as settled.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
=== Reasons for the development of multicellularity === Despite the fact that prokaryotic cells contained the building blocks required for multicellularity to arise, this transition did not occur for around 1500 million years after the origins of the first eukaryotic cell. Scientists have proposed two major theories for the reason that multicellularity arose so late after the appearance of life on Earth.
== Wallerian Degeneration == Main article: Wallerian degeneration Wallerian degeneration is a process that occurs after axonal injury. This is specifically in cases of axonotmesis and neurotmesis. It represents an innate immune response within the peripheral nervous system which is essential for preparation of regeneration. After the injury, the distal portion of the axon undergoes fragmentation, typically beginning within the first 1-2 days, this is then followed by disintegration of an axon and its myelin sheath. Schwann cells and macrophages play essential roles in this process by clearing axonal and myelin debris through phagocytosis; this is a process that occurs within 7 days and is completed within two weeks. This immune mediated response is essential for regeneration because myelin contains molecules that inhibit axonal regeneration. Schwann cells also contribute by releasing cytokines and chemokines that recruit macrophages and promote a regenerative environment. This is a process that allows regenerating axons to grow along pathways that are formed by Schwann cells. Efficient Wallerian degeneration is necessary for functional recovery, impaired or delayed immune responses can ultimately result in reduced regeneration and poorer clinical outcomes.
Michel Eugène Chevreul (French pronunciation: [miʃɛl øʒɛn ʃəvʁœl]; 31 August 1786 – 9 April 1889) was a French chemist whose work contributed to significant developments in science, medicine, and art. Chevreul's early work with animal fats revolutionized soap and candle manufacturing and led to his isolation of the heptadecanoic (margaric), stearic, and oleic fatty acids. In the process, Chevreul became the first scientist to define the concept of a chemical compound and the first to formally characterize the nature of organic compounds; he is consequently considered a founder of modern organic chemistry. In the medical field, Chevreul was first to demonstrate that diabetics excrete glucose in the urine and to isolate creatine. Chevreul's study of textile dyes while director of the Gobelins Manufactory in Paris led to color theories that "provided the scientific basis for Impressionist and Neo-Impressionist painting." Chevreul is one of the 72 French scientists, mathematicians, and engineers whose names are inscribed on the Eiffel Tower. He lived to be 102 and was a pioneer in the field of gerontology.
Sources: en.wikipedia.org
During the trial of alleged 9/11 conspirator Zacarias Moussaoui, the U.S. government identified five people as having been completely aware of the operation's details; bin Laden, Mohammed, Mohammed Atef, Abu Turab al-Urduni, and bin al-Shibh. The attacks were conceived by Khalid Sheikh Mohammed, who first presented it to bin Laden in 1996. Many targets were listed that al-Qaeda hijackers could crash planes into, including the Library Tower (now the U.S. Bank Tower) in Los Angeles. Bin Laden rejected the plan for being too elaborate. Al-Qaeda's first attacks against the U.S. after Bin Laden's 1998 fatwa were the 1998 African embassy bombings. In late 1998 or early 1999, bin Laden approved Mohammed to go forward with a new version of the 1996 plan. Bin Laden provided leadership and financial support, and was involved in selecting participants. Atef provided operational support, including target selections and helping arrange travel for the hijackers. He initially selected Nawaf al-Hazmi and Khalid al-Mihdhar, both experienced jihadists who had fought in the Bosnian war. The two arrived in the United States in mid-January 2000. In early 2000, they took flying lessons in San Diego, California. Both spoke little English. They performed poorly in flying lessons, and so they eventually served as secondary "muscle" hijackers. The Hamburg cell in Germany included Islamists who were key operatives in the 9/11 attacks. In late 1999, cell members bin al-Shibh, Mohamed Atta, Marwan al-Shehhi, and Ziad Jarrah arrived to meet al-Qaeda in Afghanistan.
Syngenta's azoxystrobin was the first product launched. BASF's F-500 Series, which includespyraclostrobin and kresoxim-methyl, and Bayer CropScience, and Monsanto are developing new compounds in this class. Combination pesticides, such as Monsanto's Genuity and SmartStax are more and more frequently used.
== History == The condition was first described by Austrian ophthalmologist Ernst Fuchs (1851–1930), after whom it is named. In 1910, Fuchs first reported 13 cases of central corneal clouding, loss of corneal sensation and the formation of epithelial bullae, or blisters, which he labeled 'dystrophia epithelialis corneae'. It was characterized by late onset, slow progression, decreased visual acuity in the morning, lack of inflammation, diffuse corneal opacity, intense centrally, and roughened epithelium with vesicle-like features. A shift to the understanding of FECD as primarily a disease of the corneal endothelium resulted after a number of observations in the 1920s. Crystal-like features of the endothelium were noted by Kraupa in 1920, who suggested that the epithelial changes were dependent on the endothelium. Using a slit lamp, Vogt described the excrescences associated with FCD as drop-like in appearance in 1921. In 1924, Graves then provided an extremely detailed explanation of the endothelial elevations visible with slit lamp biomicroscopy. A patient with unilateral epithelial dystrophy and bilateral endothelial changes was described by the Friedenwalds in 1925; subsequent involvement of the second eye led them to emphasize that endothelial changes preceded epithelial changes. As only a subset of patients with endothelial changes proceeded to epithelial involvement, Graves stated on 19 October 1925 to the New York Academy of Medicine that "Fuchs' epithelial dystrophy may be a very late sequel to severer cases of the deeper affection".
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.